167 related articles for article (PubMed ID: 16626170)
41. [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
Brotelle T; Lemal R; Moluçon-Chabrot C; Bay JO; Delaunay J; Guièze R
Bull Cancer; 2014 Feb; 101(2):211-8. PubMed ID: 24557850
[TBL] [Abstract][Full Text] [Related]
42. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
43. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.
Yu B; Liu D
Biomark Res; 2019; 7():24. PubMed ID: 31695916
[TBL] [Abstract][Full Text] [Related]
44. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.
Swaminathan M; Cortes JE
Ther Adv Hematol; 2023; 14():20406207231154708. PubMed ID: 36845850
[TBL] [Abstract][Full Text] [Related]
45. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
Sakamaki H
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
[TBL] [Abstract][Full Text] [Related]
46. Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
Zaytsev D; Girshova L; Ivanov V; Budaeva I; Motorin D; Badaev R; Mirolubova J; Grobovenko E; Chitanava T; Zaykova E; Alexeeva J; Zaritskey A
Biology (Basel); 2020 Feb; 9(2):. PubMed ID: 32050707
[TBL] [Abstract][Full Text] [Related]
47. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
48. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
49. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
Kell J
Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin.
Fostvedt LK; Hibma JE; Masters JC; Vandendries E; Ruiz-Garcia A
Clin Pharmacol Ther; 2019 Nov; 106(5):1006-1017. PubMed ID: 31070776
[TBL] [Abstract][Full Text] [Related]
51. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Gaitani S; Visani G; Baccarani M
Leuk Res; 2004 Sep; 28(9):987-90. PubMed ID: 15234577
[TBL] [Abstract][Full Text] [Related]
52. Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.
Mamolo C; Welch V; Walter RB; Cappelleri JC; Brockbank J; Cawson M; Knight C; Wilson M
Pharmacoeconomics; 2021 Jan; 39(1):121-131. PubMed ID: 33236329
[TBL] [Abstract][Full Text] [Related]
53. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
54. Mylotarg approved for patients with CD33+ acute myeloid leukemia.
Sorokin P
Clin J Oncol Nurs; 2000; 4(6):279-80. PubMed ID: 11899326
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal antibodies for the treatment of acute myeloid leukemia.
Abutalib SA; Tallman MS
Curr Pharm Biotechnol; 2006 Oct; 7(5):343-69. PubMed ID: 17076651
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
57. High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
Oya S; Ozawa H; Morishige S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Int J Hematol; 2024 Jul; ():. PubMed ID: 38963637
[TBL] [Abstract][Full Text] [Related]
58. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
[TBL] [Abstract][Full Text] [Related]
59. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Lo Coco F; Ammatuna E; Noguera N
Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371
[TBL] [Abstract][Full Text] [Related]
60. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
